In Vivo Methods to Study Uptake of Nanoparticles into the Brain

[1]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  E. Duysen,et al.  Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. , 2010, Chemico-biological interactions.

[3]  M A Vandelli,et al.  Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. Lukyanov,et al.  Fluorescent proteins and their applications in imaging living cells and tissues. , 2010, Physiological reviews.

[5]  Wenwei Tang,et al.  Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  Ciprian Catana,et al.  Small-Animal Molecular Imaging Methods , 2010, Journal of Nuclear Medicine.

[7]  Rongqin Huang,et al.  Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo , 2010, Brain Research Bulletin.

[8]  W. Banks,et al.  Transport across the Blood-Brain Barrier of Pluronic Leptin , 2010, Journal of Pharmacology and Experimental Therapeutics.

[9]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[10]  D. Paolino,et al.  A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB , 2010, Neuroscience Letters.

[11]  G. Tosi,et al.  Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[12]  Chen Jiang,et al.  Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. , 2009, Biomaterials.

[13]  A. Reichel.  Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept , 2009, Chemistry & biodiversity.

[14]  Wei Feng,et al.  Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. , 2009, International journal of pharmaceutics.

[15]  D. Begley,et al.  Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Xin-guo Jiang,et al.  Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles , 2009, Journal of drug targeting.

[17]  V. Labhasetwar,et al.  Nanoparticle‐mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia‐reperfusion injury , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  H. Tsukada,et al.  Evaluation of O-[(18)F]fluoromethyl-D-tyrosine as a radiotracer for tumor imaging with positron emission tomography. , 2009, Nuclear medicine and biology.

[19]  C. Patlak,et al.  Estimating Blood and Brain Concentrations and Blood-to-Brain Influx by Magnetic Resonance Imaging with Step-Down Infusion of Gd-DTPA in Focal Transient Cerebral Ischemia and Confirmation by Quantitative Autoradiography with Gd-[14C]DTPA , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. Kreuter,et al.  Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[21]  William A Banks,et al.  Developing drugs that can cross the blood-brain barrier: applications to Alzheimer's disease , 2008, BMC Neuroscience.

[22]  G. Golomb,et al.  Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[23]  V. Labhasetwar,et al.  TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. , 2008, Biomaterials.

[24]  N J Abbott,et al.  Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. , 2008, Current drug metabolism.

[25]  G. Schenk,et al.  Drug targeting to the brain , 2008, Annual review of pharmacology and toxicology.

[26]  K. Landfester,et al.  The First Step into the Brain: Uptake of NIO‐PBCA Nanoparticles by Endothelial Cells in vitro and in vivo, and Direct Evidence for their Blood–Brain Barrier Permeation , 2008, ChemMedChem.

[27]  R. Béliveau,et al.  Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2 , 2008, British journal of pharmacology.

[28]  Thomas Wisniewski,et al.  Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's‐disease‐model transgenic mice shown as by micromagnetic resonance imaging , 2008, Journal of neuroscience research.

[29]  Denis Guilloteau,et al.  PE2I: A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter , 2008, CNS neuroscience & therapeutics.

[30]  W. Geldenhuys,et al.  Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N′-Dodecylbispicolinium Dibromide at the Blood-Brain Barrier , 2008, Journal of Pharmacology and Experimental Therapeutics.

[31]  A. Paillard,et al.  Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro. , 2007, International journal of pharmaceutics.

[32]  M A Vandelli,et al.  Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Maxime Culot,et al.  Modelling of the blood–brain barrier in drug discovery and development , 2007, Nature Reviews Drug Discovery.

[34]  John A Butman,et al.  Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. , 2007, Neoplasia.

[35]  W. Pardridge.  Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[36]  J. Rao,et al.  Fluorescence imaging in vivo: recent advances. , 2007, Current opinion in biotechnology.

[37]  M. Michaelis,et al.  Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[38]  Susan A Charman,et al.  Methods to assess drug permeability across the blood‐brain barrier , 2006, The Journal of pharmacy and pharmacology.

[39]  A. Rawat,et al.  Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles , 2006, Journal of drug targeting (Print).

[40]  G. Tosi,et al.  Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[41]  W. Banks,et al.  Antagonists of growth hormone-releasing hormone cross the blood-brain barrier : A potential applicability to treatment of brain tumors , 2005 .

[42]  W. Geldenhuys,et al.  Brain Uptake Kinetics of Nicotine and Cotinine after Chronic Nicotine Exposure , 2005, Journal of Pharmacology and Experimental Therapeutics.

[43]  T. Nagai,et al.  Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[44]  S. Krähenbühl,et al.  Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects , 2005, Journal of drug targeting.

[45]  S. Desrayaud,et al.  The priorities/needs of the pharmaceutical industry in drug delivery to the brain , 2005 .

[46]  H. Kusuhara,et al.  Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein , 2005, Journal of Pharmacology and Experimental Therapeutics.

[47]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[48]  D. Begley,et al.  Brain Targeting Of Nerve Growth Factor Using Poly(Butylcyanoacrylate) Nanoparticles , 2004 .

[49]  N. Abbott.  Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. , 2004, Drug discovery today. Technologies.

[50]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[51]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[52]  Tian-zhi Tan,et al.  Antisense imaging of colon cancer-bearing nude mice with liposome-entrapped 99m-technetium-labeled antisense oligonucleotides of c-myc mRNA. , 2004, World journal of gastroenterology.

[53]  W. Pardridge,et al.  Log(BB), PS products and in silico models of drug brain penetration. , 2004, Drug discovery today.

[54]  S. M. Robinson,et al.  Triglycerides induce leptin resistance at the blood-brain barrier. , 2004, Diabetes.

[55]  Yiguang Jin,et al.  The Effect of RMP-7 and its Derivative on Transporting Evens Blue Liposomes into the Brain , 2004, Drug delivery.

[56]  Russell J Mumper,et al.  Brain uptake of thiamine-coated nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[57]  P. Gaillard,et al.  The role of drug transporters at the blood-brain barrier. , 2003, Annual review of pharmacology and toxicology.

[58]  J. Frangioni.  In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.

[59]  Paul R. Lockman,et al.  In Vivo and in Vitro Assessment of Baseline Blood-Brain Barrier Parameters in the Presence of Novel Nanoparticles , 2003, Pharmaceutical Research.

[60]  A. Misra,et al.  Drug delivery to the central nervous system: a review. , 2003, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[61]  Xun Sun,et al.  Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[62]  J. Brillault,et al.  Prediction of Drug Transport Through the Blood-Brain Barrier in Vivo: A Comparison Between Two in Vitro Cell Models , 2002, Pharmaceutical Research.

[63]  S. Kawakami,et al.  Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[65]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  I. Fichtner,et al.  Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models , 2001, Pharmaceutical Research.

[67]  Y. Sawada,et al.  Characteristics of Choline Transport Across the Blood-Brain Barrier in Mice: Correlation with In Vitro Data , 2000, Pharmaceutical Research.

[68]  Y. Sawada,et al.  Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. , 2000, American journal of physiology. Heart and circulatory physiology.

[69]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[70]  A. Kastin,et al.  Mahogany (1377-1428) enters brain by a saturable transport system. , 2000, The Journal of pharmacology and experimental therapeutics.

[71]  de Lange EC,et al.  Microdialysis for pharmacokinetic analysis of drug transport to the brain. , 1999, Advanced drug delivery reviews.

[72]  G. L. Curran,et al.  Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. , 1996, Brain research. Molecular brain research.

[73]  J. Ghersi-Egea,et al.  Blood-brain interfaces: relevance to cerebral drug metabolism. , 1995, Toxicology letters.

[74]  Peter L. Bonate,et al.  Animal models for studying transport across the blood-brain barrier , 1995, Journal of Neuroscience Methods.

[75]  G. Siest,et al.  Localization of Drug‐Metabolizing Enzyme Activities to Blood‐Brain Interfaces and Circumventricular Organs , 1994, Journal of neurochemistry.

[76]  W. Banks,et al.  Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.

[77]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.

[78]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[79]  S. Urien,et al.  Effects of the Binding of Imipramine to Erythrocytes and Plasma Proteins on Its Transport Through the Rat Blood‐Brain Barrier , 1988, Journal of neurochemistry.

[80]  S. Rapoport,et al.  Examination of Blood — Brain Barrier Permeability in Dementia of the Alzheimer Type with [68Ga]EDTA and Positron Emission Tomography , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[81]  A. Betz,et al.  Sucrose permeability of the blood-retinal and blood-brain barriers. Effects of diabetes, hypertonicity, and iodate. , 1986, Investigative ophthalmology & visual science.

[82]  D. Begley,et al.  Measurement of Solute Transport Across the Blood–Brain Barrier in the Perfused Guinea Pig Brain: Method and Application to N‐Methyl‐α‐Aminoisobutyric Acid , 1986, Journal of neurochemistry.

[83]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[84]  H. Hervonen,et al.  Endothelial surface sulfhydryl-groups in blood-brain barrier transport of nutrients. , 1984, Acta physiologica Scandinavica.

[85]  W. Pardridge,et al.  Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug. , 1983, The Journal of clinical investigation.

[86]  L. Brady,et al.  Analgesic effects of intraventricular morphine and enkephalins in nondependent and morphine-dependent rats. , 1982, The Journal of pharmacology and experimental therapeutics.

[87]  D. R. Bell,et al.  Albumin permeability times surface area (PS) product of peritubular capillaries in kidney , 1974, Experientia.

[88]  W H Oldendorf,et al.  Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. , 1971, The American journal of physiology.

[89]  W H Oldendorf,et al.  Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. , 1970, Brain research.

[90]  U. Bickel,et al.  How to measure drug transport across the blood-brain barrier , 2011, NeuroRX.

[91]  W. Pardridge.  The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[92]  Janine Doorduin,et al.  Evaluation of [11C]-DAA1106 for imaging and quantification of neuroinflammation in a rat model of herpes encephalitis. , 2010, Nuclear medicine and biology.

[93]  T. Aminabhavi,et al.  Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[94]  Jim E Riviere,et al.  Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[95]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[96]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[97]  Alexander V Kabanov,et al.  Nanogels for oligonucleotide delivery to the brain. , 2004, Bioconjugate chemistry.

[98]  Q. Smith,et al.  In situ brain perfusion technique. , 2003, Methods in molecular medicine.

[99]  R. Pabst,et al.  Behavioral phenotyping of mice in pharmacological and toxicological research. , 2003, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[100]  Q. Smith,et al.  A review of blood-brain barrier transport techniques. , 2003, Methods in molecular medicine.

[101]  D. Breimer,et al.  Transporters and the blood-brain barrier (BBB). , 1998, International journal of clinical pharmacology and therapeutics.